Azitra Begins Phase 1b Clinical Trial Dosing Of ATR-12 For Netherton Syndrome; Study To Enroll 12 Adults Over 14 Days With Interim Safety Data Expected In Early 2025 And Full Results In Second Half Of 2025
Portfolio Pulse from Benzinga Newsdesk
Azitra has initiated a Phase 1b clinical trial for ATR-12, targeting Netherton Syndrome. The trial will involve 12 adults over 14 days, with interim safety data expected in early 2025 and full results in the second half of 2025.
August 28, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Azitra has commenced a Phase 1b trial for ATR-12, aimed at treating Netherton Syndrome. The trial will enroll 12 adults over 14 days, with interim safety data anticipated in early 2025 and complete results in the latter half of 2025.
The initiation of a Phase 1b trial is a positive development for Azitra, indicating progress in their drug development pipeline. The anticipation of interim and full results in 2025 suggests potential future catalysts for the stock, which could drive investor interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100